Nippon Shinyaku Submits Sakigake DMD Drug Viltolarsen in Japan, Could Be Approved by March

Nippon Shinyaku said on September 26 that it has submitted a new drug application in Japan for the oligonucleotide drug viltolarsen, which was granted sakigake fast-track designation, for the treatment of Duchenne muscular dystrophy (DMD). If all goes well, it...read more